Drug Discovery

Twitter

Facebook

Copy Link

Key Facts

Key PlayersIsomorphic Labs, Recursion, Insilico

Top News

Biohub Secures $1.8 Billion for AI Biology Data to Build Universal Virtual Cell

Zuckerberg-backed Biohub announced a $1.8 billion collaboration with Google DeepMind, Meta, the U.S. Department of Energy, and the National Institutes of Health to generate AI-ready biological data. The Virtual Biology Initiative aims to build predictive AI models of biology that could compress drug development timelines from years to months by enabling scientists to digitally simulate biological systems.

Science11 sources

Biohub Secures $1.8 Billion for AI Biology Data to Build Universal Virtual Cell

Science11 sources

Danaher to Launch AI-Powered Autonomous Lab for 8x Faster Drug Discovery in 2027

Life sciences company Danaher announced plans to launch its first AI-powered autonomous lab in early 2027, promising to accelerate molecule discovery by up to 8 times. The facility at Abcam will combine AI, robotics, and technologies from multiple Danaher operating companies to develop custom antibodies and molecular tools through a continuous design-make-test-learn cycle.

Technology4 sources

Danaher to Launch AI-Powered Autonomous Lab for 8x Faster Drug Discovery in 2027

Technology4 sources

First Patient Treated in Groundbreaking Armored CAR T-Cell Therapy Trial for Ovarian Cancer

Roswell Park Comprehensive Cancer Center and Generate Biomedicines have dosed the first patient in a clinical trial evaluating GB-5267, an AI-designed IL-18 armored CAR T-cell therapy targeting MUC16 in recurrent ovarian cancer. The treatment aims to overcome immune suppression without requiring chemotherapy-based lymphodepletion.

Health2 sources

First Patient Treated in Groundbreaking Armored CAR T-Cell Therapy Trial for Ovarian Cancer

Health2 sources

Roche Commits to Autonomous AI Labs to Transform Drug Discovery and R&D Efficiency

Swiss pharmaceutical giant Roche announced plans to build autonomous AI labs aimed at accelerating drug discovery and research. The company is pursuing AI independence in R&D, with its Target Nexus tool set to contribute to 80% of portfolio decisions by end of 2026. Roche is reallocating $2.41 billion from R&D savings toward AI and productivity programs.

Technology2 sources

Roche Commits to Autonomous AI Labs to Transform Drug Discovery and R&D Efficiency

Technology2 sources

Enveda Raises $311M Series E to Advance Nature-Derived AI Drugs Into Clinical Trials

Biotech startup Enveda closed a $311 million Series E at a $2 billion valuation to advance AI-discovered drug candidates targeting severe skin conditions, weight loss maintenance, and inflammatory diseases. The Boulder-based company has moved three nature-derived compounds into human trials using its PRISM platform.

Startups2 sources

Enveda Raises $311M Series E to Advance Nature-Derived AI Drugs Into Clinical Trials

Startups2 sources

Binghamton University Secures Funding for AI-Powered Cancer Detection and Advanced RNA Drug Delivery

Two Binghamton University researchers received seed funding from the SUNY Technology Accelerator Fund to advance healthcare innovations. Nancy Guo is developing ClinSegAI, an AI model for rapid cancer biomarker detection in pathology imaging. John Fetse is creating PeptoLNP, amino acid-based lipid nanoparticles that address toxicity concerns in RNA therapeutic drug delivery.

Health2 sources

Binghamton University Secures Funding for AI-Powered Cancer Detection and Advanced RNA Drug Delivery

Health2 sources

Nvidia-Backed AI Drug Discovery Startup Iambic Therapeutics Files for Nasdaq IPO

Iambic Therapeutics, an AI drug discovery company backed by Nvidia and Qatar Investment Authority, filed for a Nasdaq IPO to advance three cancer drug candidates. The San Diego-based biotech has raised $461.8 million and uses its molecular superintelligence platform to develop treatments for solid tumors.

Business4 sources

Nvidia-Backed AI Drug Discovery Startup Iambic Therapeutics Files for Nasdaq IPO

Business4 sources

Virtual Cells Built from 4D AI Models and Digital Twins Could Speed Up Drug Discovery

University of California San Diego researchers developed two approaches to create virtual cells that mimic real biological processes. One uses a deep-learning model called MitoSpace trained on 40,000 4D movies to predict cellular health. The other builds physics-based digital twins that accurately simulate mitochondrial dynamics and drug responses.

Science3 sources

Virtual Cells Built from 4D AI Models and Digital Twins Could Speed Up Drug Discovery

Science3 sources

Anthropic's Claude AI Discovers CRISPR-Like Enzyme System in 21 Hours

Anthropic announced its Claude AI model autonomously discovered a previously unknown enzyme system with properties similar to CRISPR gene-editing technology. The discovery took just 21 hours using 950 AI agents analyzing 210 million tokens at the company's new wet biology lab in the San Francisco Bay Area.

Science26 sources

Anthropic's Claude AI Discovers CRISPR-Like Enzyme System in 21 Hours

Science26 sources

AI Agents Transform Drug Discovery: 37,000 Virtual Scientists Identify Cancer Treatments

Stanford researchers deployed 37,000 AI agents organized as a Virtual Biotech company to accelerate drug discovery. The AI co-scientists autonomously analyzed over 55,000 clinical trials and identified a promising lung cancer treatment targeting CD276 protein. Google's Co-Scientist system proposed novel cancer-fighting strategies by analyzing 700+ papers, demonstrating AI's role in scientific breakthrough.

Technology3 sources

AI Agents Transform Drug Discovery: 37,000 Virtual Scientists Identify Cancer Treatments

Technology3 sources

Twist Bioscience secures data pipeline role in Eli Lilly TuneLab's AI drug discovery ecosystem

Twist Bioscience announced a partnership with Eli Lilly TuneLab to provide antibody characterization data services for the AI/ML-driven drug discovery platform. The agreement positions Twist as a preferred data provider for AbLab, feeding high-quality wet lab data into Lilly's antibody developability prediction model used by over 75 participating biotech companies.

Technology5 sources

Twist Bioscience secures data pipeline role in Eli Lilly TuneLab's AI drug discovery ecosystem

Technology5 sources

Novo Nordisk Partners with Anthropic to Accelerate AI Drug Discovery Using Claude Science

Novo Nordisk announced a collaboration with Anthropic to use Claude AI models for drug discovery and development. The pharmaceutical giant already uses Claude to cut patient documentation time from months to minutes and now aims to compress decades of biological breakthroughs into years through AI-driven research and development.

Technology8 sources

Novo Nordisk Partners with Anthropic to Accelerate AI Drug Discovery Using Claude Science

Technology8 sources

ByteDance Spins Off AI Drug Discovery Unit Anew Labs, Secures $290M at $1.5B Valuation

ByteDance has completed a $290 million fundraising round for Anew Labs, its newly independent AI drug discovery unit, achieving a $1.5 billion valuation. The ByteDance spin-off attracted leading investors including HSG, IDG Capital, and Hillhouse Investment, while ByteDance retains 56% ownership of the Shanghai-based company.

Startups2 sources

ByteDance Spins Off AI Drug Discovery Unit Anew Labs, Secures $290M at $1.5B Valuation

Startups2 sources

Insilico Medicine Unveils AI-Driven Longevity Vaccines to Target Cellular Drivers of Age-Related Diseases

Insilico Medicine announced Longevity Vaccines, a research initiative using AI-driven drug discovery to develop single-dose therapies that eliminate senescent cells. The programmable circular RNA platform targets cellular drivers of age-related diseases, starting with immunosenescence. The company reported $106 million revenue in H1 2026, marking its first profitable half-year.

Health2 sources

Insilico Medicine Unveils AI-Driven Longevity Vaccines to Target Cellular Drivers of Age-Related Diseases

Health2 sources

AI Could Cure Cancer Within Our Lifetimes, But Chip Shortage Slows Progress, Says Arm Holdings CEO

Arm Holdings CEO Rene Haas claims AI will help find cure for cancer by solving complex biological modeling problems humans cannot. But semiconductor shortages are limiting AI data centers needed for medical breakthroughs, creating a supply-constrained environment that threatens to delay AI-driven drug discovery advances.

Technology4 sources

AI Could Cure Cancer Within Our Lifetimes, But Chip Shortage Slows Progress, Says Arm Holdings CEO

Technology4 sources

Prev12 3 4 5 Next